Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma

Documenti analoghi

• Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
  di: Qin, Haiying, et al.
  Pubblicazione: (2018)
• Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor-T Cell Therapy
  di: Shalabi, Haneen, et al.
  Pubblicazione: (2018)
• CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
  di: Shah, Nirali N., et al.
  Pubblicazione: (2020)
• Characterization of CD22 Expression in Acute Lymphoblastic Leukemia
  di: Shah, Nirali N., et al.
  Pubblicazione: (2015)
• Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma
  di: Salem, Dalia A., et al.
  Pubblicazione: (2018)